Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 68, Issue 11, Pages 1901-1907
Publisher
Springer Science and Business Media LLC
Online
2019-11-06
DOI
10.1007/s00262-019-02425-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peripheral memory T cells specific for Arginase-1
- (2019) Evelina Martinenaite et al. Cellular & Molecular Immunology
- The Balance Players of the Adaptive Immune System
- (2018) Mads Hald Andersen CANCER RESEARCH
- Clinical relevance and suppressive capacity of human MDSC subsets
- (2018) Stephan Lang et al. CLINICAL CANCER RESEARCH
- Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation
- (2018) Mia Aaboe Jørgensen et al. OncoImmunology
- Targeting macrophages: therapeutic approaches in cancer
- (2018) Luca Cassetta et al. NATURE REVIEWS DRUG DISCOVERY
- Frequent adaptive immune responses against arginase-1
- (2017) Evelina Martinenaite et al. OncoImmunology
- L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
- (2016) Roger Geiger et al. CELL
- Anti-regulatory T cells
- (2016) Mads Hald Andersen Seminars in Immunopathology
- CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment
- (2016) Evelina Martinenaite et al. OncoImmunology
- Clonal Deletion Prunes but Does Not Eliminate Self-Specific αβ CD8+ T Lymphocytes
- (2015) Wong Yu et al. IMMUNITY
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy
- (2015) M. H. Andersen JNCI-Journal of the National Cancer Institute
- HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients
- (2013) S. Munir et al. CANCER RESEARCH
- Functional characterization of Foxp3-specific spontaneous immune responses
- (2013) S K Larsen et al. LEUKEMIA
- Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells
- (2013) S Munir et al. LEUKEMIA
- Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway
- (2013) S M Ahmad et al. LEUKEMIA
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
- (2013) Shamaila Munir et al. OncoImmunology
- CD4 responses against IDO
- (2012) Mads Hald Andersen OncoImmunology
- Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients
- (2012) Jana de Boniface et al. OncoImmunology
- Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators
- (2010) R. B. Sorensen et al. BLOOD
- Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
- (2009) Paulo C. Rodriguez et al. CANCER RESEARCH
- IL-8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer
- (2009) Rita Rotondo et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started